Hyaluronan and Its Impact as New Biochemical Marker on Diagnosis and Prognosis of Lung Cancer
Maristela P Rangel, Vanessa K de Sa, Joao Roberto M Martins, Edwin R Parra, Aline Mendes, Eloisa Olivieri, Dirce M Carraro, Vera L Capelozzi. University of Sao Paulo, Sao Paulo, Brazil; Federal University of Sao Paulo, Sao Paulo, Brazil; AC Camargo Hospital, Sao Paulo, Brazil
Background: Different markers have been investigated to better discriminate lung cancer evolution. Glycosaminoglycans (GAGs) are important molecules of the extracellular matrix and many have reported that GAGs have different behaviors when in the presence of malignant tissues. In this study, we sought to examine the Hyaluronan (HA) concentration and its impact on diagnosis and/or prognosis of patients with non small cell lung cancer.
Design: HA was examined in tumoral and non-tumoral tissues from 45 patients. Their preoperative clinical stages were T1-3N0-1M0 and the mean follow-up was 19.3 months. Their histologic types were adenocarcinomas (n=23), squamous cells carcinomas (SqCC) (n=16) and large cell carcinoma (n=6). Tissue samples were dehydrated with acetone and incubated with a proteolytic enzyme. The HA chains were diluted (1:100) in blocking buffer [0.05M Tris-HCl, pH 7.4, 1% BSA]. The levels of HA were measured by a noncompetitive enzyme-linked immunosorbent assay (ELISA)-like fluorometric assay.
Results: A distinct profile of HA was observed between non-tumoral and tumoral areas. HA showed significantly higher concentration in tumoral than in normal areas (p=0.0001).
The impact of HA was tested on follow-up until death from surgery day. In Fig 2, the Kaplan-Meier survival curves shows that tissues with lower concentrations of HA have better long-term survival than those with higher concentrations (Log Rank=3,59; p=0.05).
Conclusions: The presence of higher concentrations of HA in patients with lung cancer suggest a possible role of these molecule in this pathological condition and provide a potential biochemical marker for differentiating normal from lung cancer patients as well. However, further studies are needed to determine whether or not these concentrations are able to be diagnostic/prognostic markers of lung cancer.
Wednesday, March 21, 2012 9:30 AM
Poster Session V # 287, Wednesday Morning